While Humira’s 2023 loss of exclusivity hung over AbbVie’s head for years, the ascent of the Chicago drugmaker’s immunology successors Skyrizi and Rinvoq under prior CEO Richard Gonzalez has swiftl | ...

Today's Research Daily features new research reports on 12 major stocks, including AbbVie Inc. (ABBV), Lockheed Martin ...

AbbVie has put together a dream team of eight big-selling drugs that it says will end its reliance on its blockbuster Humira – which despite tougher competition could still generate peak sales ...

The obesity medicine field has gained a new entrant, with AbbVie licensing an experimental drug from a Danish company.

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

AbbVie's strategic move into the obesity market through a partnership with Gubra A/S shows potential but won't impact revenue ...

In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

The company's cash payout ratio is about 47%, giving it plenty of room to grow its dividend. Here's the bottom line: Amgen is ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Less research equates to less business between the university and these Worcester companies, spreading the pain far beyond ...

AbbVie's diversified portfolio, including drugs from the 2019 Allergan acquisition, continues to mitigate revenue declines from Humira's patent expiration. Risks include Medicare pricing changes ...

Representative Jefferson Shreve (R-Indiana) recently bought shares of AbbVie Inc. (NYSE:ABBV). In a filing disclosed on March ...